989 related articles for article (PubMed ID: 33670304)
1. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
2. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
[TBL] [Abstract][Full Text] [Related]
3. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Norinder U; Tuck A; Norgren K; Munic Kos V
Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
[TBL] [Abstract][Full Text] [Related]
4. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
5. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
Glebov OO
FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
[TBL] [Abstract][Full Text] [Related]
6. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
Dzobo K; Chiririwa H; Dandara C; Dzobo W
OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
[TBL] [Abstract][Full Text] [Related]
11. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Bonam SR; Muller S; Bayry J; Klionsky DJ
Autophagy; 2020 Dec; 16(12):2260-2266. PubMed ID: 32522067
[TBL] [Abstract][Full Text] [Related]
12. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
13. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
14. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
More SA; Patil AS; Sakle NS; Mokale SN
Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
[TBL] [Abstract][Full Text] [Related]
16. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
17. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
18. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
Low ZY; Yip AJW; Lal SK
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
[TBL] [Abstract][Full Text] [Related]
19. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
20. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.
Bestion E; Zandi K; Belouzard S; Andreani J; Lepidi H; Novello M; Rouquairol C; Baudoin JP; Rachid M; La Scola B; Mege JL; Dubuisson J; Schinazi RF; Mezouar S; Halfon P
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]